Addressing Patient Recruitment Challenges in Microbiome Drug Development: Approach from Ongoing Phase I Trial of BMC128 in Combination with Nivolumab
Time: 11:30 am
day: Conference Day One
Details:
- Defining patient populations to support the investigation of safety and tolerability of BMC128 in combination with nivolumab, an anti-PD1 immune checkpoint inhibitor, in patients with non-small cell lung cancer (NSCLC), melanoma, or renal cell carcinoma (RCC)
- Patient identification processes, supporting preliminary findings of positive evidence of cancer therapies leveraging gut microbiota
- Additional update on preclinical IBS programme to identify promising bacterial compositions through computational analysis, with ongoing optimisation to finalise the most effective combination
